Stockscreener 앱 받기
113.17
2.38%
2.63
시장 영업 전:
114.40
1.23
+1.09%
전일 마감가:
$110.54
열려 있는:
$113.2
하루 거래량:
1.50M
Relative Volume:
1.02
시가총액:
$12.63B
수익:
$2.90B
순이익/손실:
$239.11M
주가수익비율:
53.64
EPS:
2.1097
순현금흐름:
$492.62M
1주 성능:
+1.32%
1개월 성능:
+13.28%
6개월 성능:
-3.05%
1년 성능:
+13.80%
1일 변동 폭
$110.91
$116.00
1주일 범위
$102.36
$116.00
52주 변동 폭
$81.22
$118.30
퍼킨엘머 Stock (RVTY) Company Profile
명칭
Revvity Inc
전화
781-663-6900
주소
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, A, NTRA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
113.17 | 12.63B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
572.32 | 212.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
192.50 | 135.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
539.37 | 42.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
139.74 | 39.47B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
264.69 | 37.91B | 2.50B | -226.32M | 71.51M | -1.6412 |
퍼킨엘머 Stock (RVTY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-12-09 | 개시 | Goldman | Neutral |
| 2025-10-16 | 개시 | Guggenheim | Neutral |
| 2025-05-01 | 업그레이드 | UBS | Neutral → Buy |
| 2025-01-10 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-15 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-07-08 | 개시 | Leerink Partners | Outperform |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-04 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-19 | 개시 | Raymond James | Outperform |
| 2023-05-23 | 재개 | Goldman | Buy |
모두보기
퍼킨엘머 주식(RVTY)의 최신 뉴스
Revvity Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs - FinancialContent
Revvity, Inc. (RVTY) stock price, news, quote and history - Yahoo Finance UK
Revvity, Inc. (RVTY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revvity, Inc. (RVTY) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Insider Sell Alert: Anita Gonzales Sells Shares of Revvity Inc (RVTY) - GuruFocus
How Revvity’s (RVTY) Startup Software Push and ESG Disclosures Reframe Its Competitive Positioning - simplywall.st
Revvity to Launch Signals for Startups for Emerging Biotech Companies - The Globe and Mail
Revvity Inc. Stock Slides 3.4%, Underperforms Peers - webull.com
Revvity stock holds steady as Q1 2026 growth and margin expansion underpin valuation - Ad-hoc-news.de
Precision Trading with Revvity Inc. (RVTY) Risk Zones - Stock Traders Daily
Revvity Inc (RVTY) Stock Down 3.4% -- Now Undervalued? GF Score: 72/100 - GuruFocus
Revvity Inc. stock underperforms Monday when compared to competitors - MarketWatch
Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One - 01net
RVTY (RVTY) investor files notice to sell 85 common shares - Stock Titan
Revvity (NYSE: RVTY) removes 1.875% notes due 2026 from NYSE listing - Stock Titan
Revvity launches “Signals for Startups” to give emerging biotechs an enterprise-grade digital edge - Indian Chemical News
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure - Lelezard
Revvity stock trades steadily as recent earnings highlight margin focus - Ad-hoc-news.de
PKI5144059 Bond Coupon Profile — Rate & Payments - TradingView
Revvity (NYSE: RVTY) VP Gonzales sells 85 shares under 10b5-1 plan - Stock Titan
PKI5144059 Bond Profile — Key Metrics - TradingView
XS1405780617 Bond Coupon Profile — Rate & Payments - TradingView
XS1405780617 Bond Risk Profile - TradingView
PKI5255604 Bond Risk Profile - TradingView
XS1405780617 Bond Profile — Key Metrics - TradingView
Revvity stock trades steady as genomics and diagnostics revenue underpins valuation - Ad-hoc-news.de
Revvity, Inc. (PKN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Revvity, Inc. (PKN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
PKI5255604 Bond Profile — Key Metrics - TradingView
PKI5255604 Bond Coupon Profile — Rate & Payments - TradingView
Revvity stock trades steadily as recent earnings highlight growth and margin pressure - Ad-hoc-news.de
Revvity Inc. stock outperforms competitors on strong trading day - MSN
Revvity (RVTY) Q4 2025 earnings summary - Quartr
TD Cowen Adjusts Price Target on Revvity to $130 From $120, Maintains Buy Rating - marketscreener.com
REVVITY INC : TD COWEN RAISES TARGET PRICE TO $130 FROM $120 - Moomoo
TD Cowen Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $130 - Moomoo
Revvity (RVTY) Investor Day 2024 Summary - Quartr
Revvity (RVTY) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Revvity (RVTY) Citi Annual Global Healthcare Conference 2025 Summary - Quartr
PKI4882935 Bond Risk Profile - TradingView
A184AM Bond Risk Profile - TradingView
A184AM Bond Coupon Profile — Rate & Payments - TradingView
S&P Global upgrades Revvity outlook on leverage improvement By Investing.com - Investing.com Nigeria
A184AM Bond Profile — Key Metrics - TradingView
PKI5255603 Bond Profile — Key Metrics - TradingView
S&P Global upgrades Revvity outlook on leverage improvement - Investing.com
Revvity: Overvalued On Sentiment (NYSE:RVTY) - Seeking Alpha
The path to AI federated learning for drug discovery - Scientific Computing World
Baird Adjusts Price Target on Revvity to $128 From $117, Maintains Outperform Rating - marketscreener.com
퍼킨엘머 (RVTY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
8.61%
자본화:
|
볼륨(24시간):